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It has been previously shown (1) that aureomycin, when added to a  necro- 
genie yeast diet, has a  significant beneficial effect in the prevention of experi- 
mental hepatic necrosis in rats. In contrast to vitamin E  or the suifur-contain- 
ing  amino  acids,  cystine  or methionine,  which  as  supp]ements  to  the  basal 
experimental yeast diet will permanently prevent the production of hepatic 
necrosis, the effect of aureomycin was found to be as a rule only temporary and 
more in way of a delay. 
In discussing  the possible mechanism of the aureomycin effect it has been 
emphasized (a) that intensive studies have revealed no indication of an under- 
lying infection as  the  direct  cause  of so  called  dietary hepatic  necrosis,  (b) 
that  the  choice appeared  to  lie  between  a  direct  metabolic  effect of aureo- 
mycin on the liver and its antibiotic effect on the intestinal fora, in particular 
the coliform organisms, and (c)  that this antibiotic effect in turn may prevent 
the formation of bacterial metabolites with which the liver, in the absence of 
vitamin E  or of sulfur-containing amino acids, is unable to cope. 
The beneficia] effect of aureomycin in our experiments was not limited to 
the  delay  of hepatic  necrosis  but  manifested  itself  in  a  slight  but  definite 
stimulation of growth (1). 
If the effect of aureomycin is mediated by the suppression of the intestinal 
flora,  other antimicrobial  agents  should also prove to  be effective, although 
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not  necessarily  equal  to  aureomycin,  depending  mainly  on  their  bacterial 
"spectrum"  and on  the ease with which  they may produce resistant strains. 
Thus,  it seemed advisable to study the effect of various antimicrobial agents 
on the production of dietary hepatic necrosis, especially in comparison to thet 
of aureomycin. 
In  contrast  to  necrosis,  dietary hepatic  cirrhosis may  be  produced  in  the 
presence of cystine (not of methionine) or vitamin E  (5). In consequence, vita- 
min  E  and cystine may not act for this pathologic condition in the same "de- 
toxifying" role as  they  supposedly do  in  the  prevention  of massive  hepatic 
necrosis. It appeared to be of interest to study any possible effect of aureomy- 
cin on the development of hepatic cirrhosis in rats fed the usual low protein-high 
fat diet (5) supplemented with vitamin E. 
Experimental Method 
In the experiments dealing with the production of massive hepatic necrosis (Tables I  to 
III) the same necrogenie basal diet (YSH) was used as in our previous studies (1, 6) : Yeast 
(British type of bakers' yeastl), 18; corn starch, 79; salt mixture g.s.P. H, 3. Peanut oil, 0.5 
ml., and cod liver oil, 2 drops, were added to 8 gin. of the dry mixture just before feeding. 
Further, all animals received daily supplements of 20 t~g. of thiamine, 25 ug. of riboflavin, 20 
ug. of pyridoxine, and 100 ug. of calcium pantothenate dissolved together in 1 hal. of water, as 
well as 20 #g. of vitamin K (menadione). Rats were of the Sprague-Dawley strain, males, with 
an average initial weight of 50.0 to 56.0 gin. in the various subgroups.  In one subgroup of 
Experiment 50 (Table II), 5 parts of pectin was substituted for equal parts of corn starch, 
the total percentage of the latter being thus reduced to 74. As antimicrobiai supplements  2 we 
used aureomydn, polymyxin, streptomycin, chloromycetin (synthetic, crystalline), terramy- 
cin, penicillin, all in doses of 2S nag. daily per rat. The antibiotics were given by mouth, with 
the exception of penicillin which was administered by injection. One subgroup in Experiment 
51 received suffaguanidine, admixed to the diet 1:100. The experiments were carried out be- 
tween November, 1949, and May, i950. 
Streptomyces grlseus and aurefaciens are producers not only of antibiotics, streptomycin 
and aureomycin respectively, but also of BI~. In consequence, the possibility  that aureomycin 
and streptomycin may contain traces of B12 had to be considered. In this connection  the fact 
that yeast, which is the chief constituent of the basal necrogenic diet, is free from Bx2 should 
also be borne in mind. We tested the effect of B~ as supplement (5 ~g. daily per rat) in two 
subgroups of Experiment 50, one with, and the other without, additional aureomycin. 
The subgroups in the various experiments  consisted of 12 to 14 animals. 
In Experiment 53 (Table IV) the effect of aureomycin (25 mg. daily per rat) was tested on 
the development of dietary hepatic cirrhosis.  The ration  (LVI)  consisted  of vitamin-free 
casein  (General Biochemicals, Inc., Chagrin  Falls, Ohio),  8; sucrose, 48; lard, 38; cod liver 
oil, 2; salt mixture (u.s.P. II), 4; niacin, 0.01, with supplements of crystalline B vitamins and 
of vitamin K as given in the experiments  on massive hepatic necrosis. Male and female rats 
(10 animals in each subgroup) of the Sprague-Dawley strain, weighing approximately  150 gin. 
were used. All surviving rats were killed after 100 days in the experiment. 
1 "D.C.L. vitamin B1 yeast" from Distillers  Corporation, Ltd., Glasgow C4, Great Britain. 
2 Aureomycin was kindly furnished  by the Lederle Laboratories, Inc., polymyxin by Bur- 
roughs  Wellcome Laboratories, chloromycetin  by Parke, Davis and Co., and terramycin by 
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In all experiments the rats were kept in single cages, with raised, wide-meshed screen bot- 
toms. The daily food intake was measured. 
At the end of the experiments an autopsy was performed on all the animals. The findings 
observable in the gross were recorded; liver, and in Experiment 53, also kidneys, pancreas, 
and thyroid glands, were subjected to histological examination. 
EXPERIM~ENTAL  OBSERVATIONS 
Massive  Hepatic  Necrosis.--The  relevant  data  are  summarized  in  Tables 
I  to III. Compared with our previous observations (1)  the survival time of the 
rats fed the experimental necrogenic diet was considerably reduced,  from an 
average of 141 days (1)  to 34 to 43 days in the more recent studies. It may be 
assumed that this difference is due to the higher average initial weight of the 
TABLE I 
The Effect of Aureom3~in, Streptomycin, and Polymyxin on Massive Hepatic Necrosis. 
Experiment 48 
Controls 
(13) 
Aureomycin 
(14) 
Polymyxin 
(15) 
Streptomycin 
04) 
Survival  time 
days 
34.3  4-  2.4* 
110  4-  13.0 
35.9  4-  1.8 
30.0  4-  1.15 
Average 
initial 
weight 
gm, 
[.0  4-  1.] 
L2  -4-  OA 
l.O  4-  0..  c 
).0  4-  OA 
Weight gait 
during 
first 4 wks. 
gm. 
4.4  4-  1.3 
24.0  4-  1.0 
12.0  4-  1.0, 
25.5  4-  0.9 
Food intake (average) during 
1-4  wks--  5-8 wks.  9-12 wks.  13-16  wks__.. 
gm.  lgm.]gm,  gm. 
5.4-4-0.1  --  -- 
5.7  4- 0.037.0  4-4- 0.056.7  4-  0.036.7  4-4- 0.1 
5.5  4-  0.04  -- 
5.44-0.036.14-0.1 
17-20 wks. 
g~. 
w 
6.54-O.04 
* Standard error of the mean. 
experimental animals in the older experiment,  138 gm., contrasted with 50 to 
54 gm. in the present experiments. It has been previously shown by Himsworth 
and Lindan  (7)  that old rats are more resistant  to dietary massive necrosis, 
presumably because of their high initial  vitamin E  stocks which will afford a 
more prolonged protection, in contrast to younger animals  with their smaUer 
vitamin E  reserves. 
Not only the control animals but also the  experimental rats receiving sup- 
plements  of  aureomycin  to  their  basal  diet  showed  reduced  survival  times 
when compared with that of the animals in the previous study (1). Here again, 
this finding may be related to the difference in the  initial weights. In Experi- 
ment 48 (Table I) and Experiment 50 (Table II) the survival rate of the  ani- 
mals receiving supplements of aureomycin  was  110  days, that of the control 
animals 34  to 41  days. 
In Experiment 48  (Table I) we compared aureomycin with polymyxin and 
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aureomycin very significantly effective. The delay in the production d  massive 
necrosis  by  aureomycin  becomes  particularly  evident  when  the  number  of 
surviving animals  is charted  in relation  to days of survival  (Fig.  1).  As seen 
TABLE II 
The E.ffect of Aureomycin, Bls, Streptomycin, and Pectin on Massive Hepatic Necrosis. 
7.ontrols (14) 
Bn (13) 
aureomycin (13) 
%ureomycin  and  Bt* 
(t4) 
~treptomycin (14) 
~treptomycin and 
pectin (14) 
Survival 
time 
days 
41.3  4-  1.45 
43.4  ~  3.2 
110.7  ..4- 10.2 
96.8  -4-  9.0 
56.0  .4-  3.5 
71.0  -4-  6.4 
E± 
Average 
initial 
weight 
gin. 
$0.0  ~  0.75 
50.0  -4- 0.8 
50.9  .4-  1.15 
50.0  .4-  0.7 
50.5  .4-  0.8 
$0.0  .4. 0.7 
,erim~nt 50 
Weight gain  du  ?t 
gftL 
7.0  -4-  1.1 
10.5  4-  1.0 
27.0  ~  1.2 
23.6 -4- 0.85 
12.5  .4-  0.8 
14.0  .4-  1.1 
Food intake (average) during 
1-  wks.  5- 5 w/u.  9- L2 wks. 
gm.  gm.  gm. 
6.4  -4- 0.1  --  -- 
6,6 -a  0.1  -- 
6.6 ..4- 0.05 6.4  .-b  0.05 6.7  ..4- 0.05 
6.8  .4-  0.1  6.5  .4-  0.05 6.8  .4-  0.0 
6.6  -4- 0.05 6,5  -4- 0.1 
6.7  .4-  0.1  6.5  -4- 0.1 
13--16 wlts. 
m 
6.8  q-  0.0~ 
6.8  -4- 0.01 
m 
TABLE IH 
The Effect of Ctdaramycdin, Terramycin, Penicillin, and Sulfaguanidine on Massiw Hepatic Necrosis. 
Experimanl 51 
!  Controls 
t  (12) 
Chloromycetin 
(14) 
• Sulfaguanidine 
i'.  (13) 
~ Terramycin 
i:  (14) 
Penicillin 
(14) 
Survival time 
days 
42.8  4-  1.2 
41.3  4-  1.3 
50.8  ±  3.0 
65.0*  4-  5.3 
42.1  .4-  2.6 
Average initial 
weight 
54.0  4- 0.9 
54.3  -4- 0.65 
53.0  4-4- 0.75 
53.1  4-4- 0.55 
56.0  ...i- 0.7 
Weight gain 
during first 4 
weeks. 
6.2  -4- 2.0 
16.0  4-  1.15 
14.8  4-  1.5 
18.7  4-4- 1.0 
17.6  .4-  1.15 
Food intake (average) during 
1-4 wks. 
gm. 
6.44-4- 0.1 
6.5  4-4- 0.05 
6.3  .-I-- 0.1 
6.2  -4- 0.05 
6.5  4-4- 0.1 
5-S wks. 
gm. 
6.1  4-0.3 
6.4  4-4- 0.1 
6.8  4-  0.1 
9-12 
wks. 
,64- 
0.1 
13-16 
w  h. 
* Four rats included died after 36, 45, 80, and 122 days from volvulus of the sigmoid, without 
hepatic necrosis. 
from the data of Experiment  50  (Table  II) supplements  of Bn had no effect 
on  the  production  of dietary  massive  necrosis,  regardless  of whether  it  was 
added  to  the  basal  diet  (8)  or to the  basal  diet  already  supplemented  with 
aureomycin. Thus, the effect of aureomycin could not be due to "contamina- 
tion" with B,~. In Experiment 50 the beneficial effect of streptomycin was more 
pronounced than  in Experiment  48, and became even further  accentuated in 
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In Experiment  51  (Table III)  the findings  with chloromycetin, sulfaguani- 
dine, terramycin, and penicillin  are summarized. Chloromycetin and penicillin 
were  ineffective,  whereas sulfaguanidine  showed only slight  indication  of a 
positive effect. In contrast, terramycin, although not as effective as aureomycin 
in the previous experiments, was found to exhibit a significant  delaying effect 
on the development of massive hepatic necrosis. 
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DAY6  OF  SURVIVAL 
FIo.  1.  Days of survival in groups of rats receiving the necrogenic basal diet with and 
without supplements of antibiotics. 
Dilated cecum and  colon  were often seen in rats receiving  supplements of 
aureomycin or terramycin to the basal yeast diet. The distention of the large 
intestine was especially pronounced in rats receiving  terramycin. Four animals 
in  this  group  (Experiment  51)  appeared  to have died from volvulus of the 
colon  (two with perforation), without signs  of simultaneous hepatic necrosis. 
All other rats (control and experimental animals)  which died during the course 
of Experiments 48, 50, and 51 have shown gross and microscopic  evidence of 
massive hemorrhagic necrosis of the liver, with all its characteristic manifesta- 
tions, including  its often demonstrable prevalence in the left hal/of the liver 
(6, 9). 
All  the  antimicrobial  agents  used have  stimulated  gain  in  weight  of the 
animals during the first 4 weeks of the experiments (Tables I to III). Although 518  ANTIMICROBIAL  AGENTS  AND  DIETARY  HEPATIC  INJURY 
penicillin, chloromycetin, and polymyxin had no beneficial effect, and sulfa- 
guanidine had barely any beneficial effect on hepatic necrosis, their growth- 
stimulating effect was as great as that of streptomycin, terramycin, and aureo- 
mycin, which--in  this  order  of  least  to  greatest--were  found significantly 
beneficial in delaying the production of massive hepatic necrosis. The difference 
in growth stimulation could not be correlated with the average daily food in- 
take during the same experimental period (Tables I  to III). 
Diffuse Hepatic Fibrosis (Cirrhosis).--In two control groups of rats (10 males, 
10 females) fed a  cirrhosis-producing diet  (LVI)  cirrhosis was observed in 9 
males and in 10 females at the end of the experimental period (100 days), with 
a high incidence of ascites in both groups (Table IV). 
TABLE IV 
Incidence of Cirrhosis in Rats Fed a Cirrhosis-Producing Diet with and without Supplement of 
Aureomycin. Experiment 53 
No. 
i  of 
Diet  ani- 
mals 
LVI  10 
LVI  and  aureo-  10 
mycin  i 
LVI  [  10 
LVI and aureo-  tO 
mycin 
Sex 
M 
M 
Average weight 
II Liti d  ~inal 
gm.  gm. 
158 ±  2.5 116 =~  11.0 
160  ±  2.9 176 -4-  6.5 
157  -4-  2.0 123 -4-  6.4 
157  =k  1.8 176 -4-  3.6 
Food intake (average) during 
Cirrho- 
sis* 
I -~  wks.  5-8 w~s. 
gm.  gm. 
5.7  .4-  0.2 L0 .4-  0.2 
6.2  -~ 0.2 5.3  -4-  1.2 
6.0  .4-  0.2 ~.14-  0.2 
6.5  ~  0.2 5.7  -4- 0.2 
I 
9-I  '~ks.  13-1  wks.  0'-4-+ 
gm.  gm. 
3.5  -4- 0.3 4.3  -4- 0.2  1 --  9 
5.5  -4- 0.2 6.2 -4- 0.~  10 --  0 
3.7  -4-  0.33.8  -4-  0.4  0--10 
5.34-0.36.1=1=0.2  7  I  2 
Kidney 
As-  injury 
cites, 
o  + 
5  0  10 
0  10  0 
9  0  10 
1  8  2 
* No attempt has been made to grade the cirrhosis beyond the initial (-4-) and pronounced (+) changes. 
The histological examination revealed the typical picture  of experimental 
dietary cirrhosis (5) in accordance with the findings in the gross. Typical mani- 
festations of acute necrotizing nephrosis accompanied the hepatic changes, as 
previously described (5). No significant alterations were found in the pancreas; 
the basophilia of the cytoplasm was in all instances well preserved. 
Two other groups of rats  (10 males,  10 females)  received the same basal 
cirrhosis-producing diet (LVI) as the above group, supplemented with 25 mg. 
aureomycin (mixed with the diet). As can be readily seen from the tabulated 
data (Table IV), cirrhotic changes in the liver as well as ascites were conspicu- 
ous by their virtual absence. Microscopic examination showed definite but not 
excessive fat infiltration of liver cells, and, with the exception of 3 rats in the 
group of female animals, no concomitant cirrhotic changes. In one of the 3 
rats  with cirrhosis,  the fibrotic proliferation was very slight. Renal  changes 
were observed in only two of the animals, with definite cirrhosis of the liver. 
The pancreas was normal in all the animals. GY(JROY, STOKES, GOLDBLATT~ AND POPPER  519 
The average food intake was higher in the groups of animals receiving sup- 
plements of aureomycin, especially in the latter part  of the experiment. The 
average weight curve showed decrease in the control animals, and statistically 
significant increase in the rats receiving supplements of aureomycin. 
The thyroid glands were studied microscopically. In both groups, the thyroid 
glands were not entirely normal. In both, they were the seat of hypertrophy 
and hyperplasia. This was of very slight degree in the group on the cirrhosis- 
producing diet alone, and of slight degree in the group that also received aureo- 
mycin. The  difference between  the  two groups was, nevertheless, definitely 
recognizable. 
DISCUSSION 
In the experiments here reported, our previous findings (1) on the beneficial 
effect of aureomycin in the partial prevention of dietary massive necrosis of 
the liver have been confirmed and expanded. It has been shown that whereas 
young animals fed the basal necrogenic yeast diet succumbed to massive ne- 
crosis in about 35 to 42 days, supplements of aureomycin prolonged the sur- 
vival time up to 110 days. 
In analyzing this aureomycin effect, several possibilities might be taken into 
consideration: (a)  the presence of a  missing, antinecrogenic substance,  (b)  a 
direct metabolic effect, and, (c) an antimicrobial effect on the intestinal flora. 
As one possible "contaminant" we have used B~ as a supplement to the basal 
diet, with or without added aureomycin, and found it without any appreciable 
effect. Although a direct metabolic effect of aureomycin could not be definitely 
excluded, and it still remains a possibility, we were inclined to favor the third 
possibility, i.e., the interaction between aureomycin and intestinal flora. It has 
been previously pointed out (1) that the temporary protection exerted by aureo- 
mycin, in contrast to the permanent protection achieved by the sulfur-contain- 
ing amino acids, 'or vitamin E, tallies especially well with the assumption that 
the effect of aureomycin is mediated through the intestinal flora. One can con- 
sider that aureomycin acts through suppression of the intestinal flora, or at 
least of some of its constituents, and thus prevents the formation of bacterial 
metabolites with which  the liver, in the  absence of vitamin E  or of sulfur- 
containing amino acids as "detoxifying agents," is unable to cope. If this as- 
sumption is correct, one can expect that such an effect will slowly wear off and 
that  organisms may reappear  in  the  intestinal flora which  are  resistant  to 
aureomycin. 
If aureomycin acts, albeit temporarily, ~/a suppression of the intestinal flora, 
some of the other known antimicrobial agents should exert a comparable delay- 
ing effect on the production of massive hepatic necrosis. Penicillin, polymyxin, 
and chloromycetin were inactive, sulfaguanidine showed only slight indication 
of a positive effect, whereas streptomycin and terramycin--in increasing order-- 
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For all practical purposes, ingested streptomycin is not absorbed from the 
intestinal  tract. Thus, its beneficial  effect further suggests suppression of the 
intestinal flora, as the mode of action. Combination with pectin increases  the 
sterilizing  effect of streptomycin in the intestine  (10).  Such combination has 
been found more effective than  streptomycin alone in delaying  massive he- 
patic necrosis  (Table II). 
If we assume that antimicrobial agents act via suppression of the intestinal 
flora,  then the quantitative differences  in their activity may be due either to 
differences in their ability to suppress those constituents of the intestinal flora 
which are essential  for the production of hepatic necrosis,  or to corresponding 
variations in the development of drug-resistant strains. 
The nutritional effect of antimicrobial agents, when added to the necrogenic 
diet,  was not limited  to  the delayed appearance  of hepatic necrosis,  but it 
manifested itself also in promotion of growth, especially during the first weeks 
of the experiments. This gain in weight was obtained not only with aureomycin 
(1),  but also with all other antimicrobial  agents,  irrespective of their  effect 
on hepatic necrosis. These findings are in accord with observations on growth 
promotion by succinylsulfathiazole  and  streptomycin  (11),  by phenylarsonic 
acid derivatives (12), and with the more recent reports on growth stimulation 
by aureomycin and the  so called  animal  protein  factor,  containing  Br~ and 
aureomycin (13). In general,  in the experiments carried out on chicks, turkeys, 
rats,  and pigs,  aureomycin appeared to be more potent than  the other anti: 
microbial agents. At present, in the absence of exact bacteriological informa- 
tion regarding  the effect of the various antimicrobial agents on the intestinal 
flora, it is impossible to explain the discrepancy between their effect on hepatic 
necrosis and on growth. 
It  is equally difficult  to  attribute  the  beneficial  effect of aureomycin  on 
hepatic necrosis  and on hepatic cirrhosis  to one common factor. For hepatic 
necrosis the possibility was discussed that in the absence of vitamin E or cystine 
as detoxifying agents, metabolites of the intestinal flora may injure the hepatic 
parenchyma. Inasmuch as cirrhosis develops in the presence of vitamin E and 
cystine (5)  these detoxifying agents should be available in sufficient  amount 
to prevent hepatic injury by metabolites of the intestinal flora. The fact that 
aureomycin stiU will prevent the development of hepatic  cirrhosis,  presents 
various possibilities :-- 
1.  The intestinal flora might play a role in the production of cirrhosis;  how- 
ever,  the "toxic" metabolites in  question must be different from those sup- 
posedly instrumental  in the production of necrosis  and are not detoxified  by 
vitamin E  or cystine. 
2.  Aureomycin may act systemically, perhaps through the endocrine  system 
or through direct metabolic reactions.  In this connection it should be pointed 
out that  in  our experiment  rats  receiving  aureomycin ate more and  gained GYORGY, STOKES, OOLDBLATT, AND POPPER  521 
more weight than the control  animals.  There was  a  slight but recognizable 
difference in the thyroid glands between  the control animals and the rats re- 
ceiving supplements  of aureomycin, with hypertrophy and hyperplasia more 
marked in the animals receiving aureomycin. This is especially noteworthy in 
view of the prevention of dietary cirrhosis  of the liver by goitrogenic  sub- 
stances  (14).  ° 
3.  Finally, the possibility  of a  "contaminant"  present in aureomycin and 
acting as an anticirrhotic agent still cannot be excluded. For the elucidation 
of the effect of aureomycin in cirrhosis, further experiments,  including  paired- 
feeding experiments, are required. 
The observations  of Opie (15) on  the intensification  and modification  of 
toxic necrosis and cirrhosis of the liver by intravenously administered cultures 
of E. coli or streptococcus  may have a bearing  on the findings here reported. 
During recent years pancreatic changes accompanying dietary cirrhosis have 
been described by several authors (16). In the present experiments, in rats fed 
the cirrhosis-producing  basal  diet for 100 days, the pancreas  appeared to be 
histologically normal despite  the severe cirrhosis of the liver. The absence of 
pancreatic changes may be due to the relatively short duration of our experi- 
ment. If this explains such absence of pancreatic changes, the presented find- 
ings would indicate that cirrhosis precedes pancreatic changes, at least under 
the experimental  conditions chosen. 
The beneficial effect of aureomycin on rats kept on a  cirrhosis-producing 
diet manifested itself in the prevention not only of cirrhosis of the liver but 
also of renal changes (5). 
S~A.RY 
The effect of various antimicrobial  agents, such as aureomycin, terramycin, 
streptomycin, chloromycetin, penicillin, polymyxin, and sulfaguanidine on the 
development of massive dietary necrosis of the liver in rats has been studied. 
Delay in the production of hepatic necrosis was  obtained from aureomycin 
and, to a lesser extent, from terramycin and streptomycin. Indication of tem- 
porary protection was shown by sulfaguanidine,  whereas chloromycetin,  poly- 
myxin, and penicillin were not protective. 
1312, added alone, or in combination  with aureomycin, to the basal experimental 
diet had no influence on the development of hepatic necrosis. A combination of 
pectin with streptomycin enhanced the protective effect of the antibiotic. 
All the antimicrobial agents tested, without relation to their effect on hepatic 
necrosis, produced temporary stimulation of growth in the experimental  ani- 
mals. 
The beneficial effect of aureomycin was not limited to the delay of hepatic 
necrosis but manifested itself also in the prevention of hepatic cirrhosis in rats 
fed a low protein (casein)-high  fat diet. In contrast to control animals  show- 522  ANTIMICROBIAL  AGENTS AND DIETARY HEPATIC  INJURY 
ing the usual combination of cirrhosis and renal changes, the rats receiving 
supplements of aureomycin were free of both cirrhosis and renal changes. The 
rats receiving aureomycin took more food in and gained weight. 
No microscopic alterations were seen in the pancreas of the control rats with 
cirrhosis. 
In  both  groups  of experiments  (necrosis  and  cirrhosis)  the  antimicrobial 
agents, with the exception of penicillin, were given mixed with the food. Their 
possible effect on the intestinal flora is discussed. 
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